Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

2003 ◽  
Vol 189 (1) ◽  
pp. 28-36 ◽  
Author(s):  
Volker J. Möbus ◽  
Richard P. Baum ◽  
Marcus Bolle ◽  
Rolf Kreienberg ◽  
Antoine A. Noujaim ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Immune Responses ◽  
Recurrent Ovarian Cancer ◽  
Murine Monoclonal Antibody ◽  
Prolonged Survival

Resection Guided by Antibodies (REGAJ) a Reappraisal after 10 Years

1998 ◽  
Vol 13 (4) ◽  
pp. 221-223 ◽  
Author(s):  
W. Jäger ◽  
S. Ackermann
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Retrospective Analysis ◽  
Ovarian Tumors ◽  
Murine Monoclonal Antibody ◽  
Ca 125 ◽  
Clinical Value ◽  
Second Look

Between 1986 and 1990 50 patients with ovarian cancer were submitted to a procedure which we called REGAJ - resection guided by antibodies. Using the radiolabeled murine monoclonal antibody OC 125, microscopic ovarian tumors producing CA 125 were detected during second-look surgery by a hand-held probe. Retrospective analysis after 10 years revealed that this procedure resulted in the cure of 4 of 11 patients, who would otherwise have been considered tumor free during second-look surgery and not further treated. Previous problems associated with the method can now be solved so that the clinical value of the procedure should be reconsidered.

Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125

1990 ◽  
Vol 38 (2) ◽  
pp. 244-248 ◽  
Author(s):  
Michael G. Muto ◽  
Neil J. Finkler ◽  
Amin I. Kassis ◽  
Eva Marie Lepisto ◽  
Robert C. Knapp
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Cancer Patients ◽  
Antibody Responses ◽  
Murine Monoclonal Antibody ◽  
Murine Antibody

scholarly journals Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients

2020 ◽  
Vol 69 (10) ◽  
pp. 2001-2007
Author(s):  
Kayoko Waki ◽  
Kanako Yokomizo ◽  
Kouichiro Kawano ◽  
Naotake Tsuda ◽  
Nobukazu Komatsu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Apoptotic Cell ◽  
Recurrent Ovarian Cancer ◽  
Vaccine Therapy ◽  
Plasma Dna ◽  
Necrotic Cell ◽  
Clinical Benefits

Abstract Cancer immunotherapy including vaccine therapy is a promising modality for cancer treatment, but few patients show its clinical benefits currently. The identification of biomarkers that can identify patients who will benefit from cancer immunotherapy is thus important. Here, we investigated the potential utility of the circulating cell-free DNA (cfDNA) integrity—a ratio of necrotic cell-derived, longer DNA fragments versus apoptotic cell-derived shorter fragments of Alu gene—as a biomarker of vaccine therapy for patients with ovarian cancer. We analyzed plasma samples from 39 patients with advanced or recurrent ovarian cancer enrolled in clinical trials for personalized peptide vaccinations. We observed that (1) the cfDNA integrity was decreased after the first cycle of vaccination, and (2) the decreased levels of cfDNA integrity were correlated with vaccine-induced immune responses; i.e., decreased cfDNA integrity was observed in 91.7% and 59.3% of the IgG-positive and negative patients, respectively (p = 0.0445). Similarly, decreased cfDNA integrity was observed in 92.9% and 56.0% of CTL response-positive and negative patients, respectively (p = 0.0283). These results suggest that the circulating cfDNA integrity is a possible biomarker for cancer vaccine therapy.

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

2004 ◽  
Vol 94 (2) ◽  
pp. 340-351 ◽  
Author(s):  
Alan N Gordon ◽  
Birgit C Schultes ◽  
Holly Gallion ◽  
Robert Edwards ◽  
Theresa L Whiteside ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
T Cell Responses ◽  
Recurrent Ovarian Cancer ◽  
Prolonged Survival ◽  
Cell Responses
Sign in / Sign up

Export Citation Format

Share Document